Tuberculosis and Chest Service, Department of Health, Hong Kong SAR, China.
Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.
We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.
我们评估了利奈唑胺治疗方案，在连续 10 例广泛耐药或氟喹诺酮类耐药耐多药结核患者中，在痰培养结果和药物耐受情况的指导下，初始剂量为 800mg 每日一次，持续 1-4 个月，然后根据情况转为 1200mg 每周三次，持续至少 1 年。在个体化优化方案的基础上，同时加用利奈唑胺。所有患者均获得稳定治愈，贫血得到纠正，神经病变稳定、改善或避免了药物的不良反应。血清利奈唑胺浓度谱优化得更好。
